British Space Startup Mass Balance Launches Longevity Lab Into Orbit to Study Disease-Causing Proteins

On Tuesday morning, British startup Mass Balance successfully launched its autonomous longevity lab into orbit aboard a SpaceX transporter. This grapefruit-sized apparatus is designed to conduct self-run chemical experiments in microgravity, aiming to gather crucial data on disease-causing proteins that are challenging to study on Earth.

Innovative Experiments in Microgravity

The Mass Balance lab, encased in a 10-centimeter pod built by Austrian company Tumbleweed, is expected to orbit Earth for several months. It will automatically measure and transmit data regarding the growth and reactions of live cells under weak gravity conditions. The goal is to collect high-quality data that is often muddied by the effects of Earth's stronger gravity, such as convection and sedimentation.

CEO Toby Call stated, “When you take away gravity, a lot of weird and wonderful things happen, some of which will be very valuable for life sciences and pharma.” This venture is part of a broader trend where microgravity is being explored as a potential tool for advancing scientific research.

Targeting Age-Related Diseases

The research conducted by Mass Balance aims to shed light on disordered proteins linked to age-related diseases like Alzheimer’s, Parkinson’s, and specific cancers. These proteins are notoriously difficult to image on Earth due to their constantly changing shapes, creating gaps in the training data for AI models such as Google’s AlphaFold.

In space, scientists hope that studying these proteins will provide clearer insights, enabling better predictions of how they respond to various treatments. Call’s vision includes using data from these experiments to train an AI model that can help fill in the gaps in current understanding.

Challenges and Opportunities in Space Biotechnology

While Mass Balance is not planning to bring its system back to Earth, this strategy alleviates some engineering challenges associated with re-entry. The initial phase of testing involves sending an industrial biocatalyst into orbit to break down another chemical compound, monitored through light to ensure the reaction proceeds as planned.

Other biotech startups are also venturing into space for research. For instance, BioOrbit launched a unit in May to grow ultra-pure crystals for cancer medications, and Varda Space Industries is developing methods for processing pharmaceuticals in microgravity. Mass Balance believes that microgravity remains an underutilized resource for scientific advancement.